{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:05:53Z","timestamp":1791558353367,"version":"4.3.4"},"reference-count":15,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,4,20]]},"abstract":"<jats:p>\n                    Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer in the open-label phase III SOLO3 trial (ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02282020\">NCT02282020<\/jats:ext-link>\n                    ). We report final overall survival (OS; prespecified secondary end point), post hoc OS analysis by number of previous chemotherapy lines, and exploratory BRCA reversion mutation analysis. Two hundred sixty-six patients were randomly assigned 2:1 to olaparib tablets (300 mg twice daily; n = 178) or physician's choice of single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan; n = 88). OS was similar with olaparib versus chemotherapy (hazard ratio [HR], 1.07 [95% CI, 0.76 to 1.49];\n                    <jats:italic>P<\/jats:italic>\n                    = .71, median 34.9 and 32.9 months, respectively, full analysis set). OS with olaparib was favorable in patients with two previous chemotherapy lines (HR, 0.83 [olaparib\n                    <jats:italic>v<\/jats:italic>\n                    chemotherapy] [95% CI, 0.51 to 1.38]; median 37.9\n                    <jats:italic>v<\/jats:italic>\n                    28.8 months); however, a potential detrimental effect was seen in patients with at least three previous chemotherapy lines (HR, 1.33 [95% CI, 0.84 to 2.18]; median 29.9\n                    <jats:italic>v<\/jats:italic>\n                    39.4 months). BRCA reversion mutations might have contributed to this finding. No patient randomly assigned to olaparib with a BRCA reversion mutation detected at baseline (6 of 170 [3.5%]) achieved an objective tumor response.\n                  <\/jats:p>","DOI":"10.1200\/jco.24.00933","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T22:59:26Z","timestamp":1734044366000},"page":"1408-1416","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":12,"title":["Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct02282020","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-9041","authenticated-orcid":true,"given":"Giovanni","family":"Scambia","sequence":"first","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5669-7132","authenticated-orcid":true,"given":"Ricardo","family":"Villalobos Valencia","sequence":"additional","affiliation":[{"name":"Centro Medico Dalinde, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-715X","authenticated-orcid":true,"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy"},{"name":"Gynecologic Oncology Program European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-9356","authenticated-orcid":true,"given":"David","family":"Cibula","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-6845","authenticated-orcid":true,"suffix":"III","given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[{"name":"O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Bidzi\u0144ski","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-9436","authenticated-orcid":true,"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Hyun","family":"Nam","sequence":"additional","affiliation":[{"name":"Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2795-4168","authenticated-orcid":false,"given":"Radoslaw","family":"Madry","sequence":"additional","affiliation":[{"name":"Poznan University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Oaxaca Site Management Organization, Oaxaca de Juarez, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1756-3320","authenticated-orcid":true,"given":"Paulo A.R.","family":"Mora","sequence":"additional","affiliation":[{"name":"Instituto COI de Educa\u00e7\u00e3o e Pesquisa, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Young","family":"Ryu","sequence":"additional","affiliation":[{"name":"Korea Institute of Radiological and Medical Sciences, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Lin","family":"Ah-See","sequence":"additional","affiliation":[{"name":"Oncology R&amp;D, Late-stage Development, AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Oncology R&amp;D, Late-stage Development, AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6678-0072","authenticated-orcid":true,"given":"Natalia","family":"Lukashchuk","sequence":"additional","affiliation":[{"name":"Translational Medicine, Oncology R&amp;D, AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Carter","sequence":"additional","affiliation":[{"name":"Biostatistics, Oncology Biometrics, Oncology R&amp;D, AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-8588","authenticated-orcid":true,"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2728"},{"key":"e_1_3_9_3_2","volume-title":"LYNPARZA\u00ae (Olaparib) Tablets, for Oral Use: Prescribing Information","author":"AstraZeneca","year":"2022","unstructured":"AstraZeneca: LYNPARZA\u00ae (Olaparib) Tablets, for Oral Use: Prescribing Information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208558s009lbl.pdf"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.12.020"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02745"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.470"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1485"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082054"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0715"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00122-X"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5559"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.646"},{"key":"e_1_3_9_13_2","volume-title":"Dear Health Care Provider Letter (Rucaparib)","author":"Clovis Oncology","year":"2022","unstructured":"Clovis Oncology: Dear Health Care Provider Letter (Rucaparib). 2022. https:\/\/clovisoncology.com\/pdfs\/US_DHCPL_final_signed.pdf"},{"key":"e_1_3_9_14_2","volume-title":"Dear Health Care Provider Letter (Olaparib)","author":"AstraZeneca","year":"2022","unstructured":"AstraZeneca: Dear Health Care Provider Letter (Olaparib). 2022. https:\/\/www.lynparzahcp.com\/content\/dam\/physician-services\/us\/590-lynparza-hcp-branded\/hcp-global\/pdf\/solo3-dhcp-final-signed.pdf"},{"key":"e_1_3_9_15_2","volume-title":"Dear Health Care Provider Letter (Niraparib)","author":"GlaxoSmithKline","year":"2022","unstructured":"GlaxoSmithKline: Dear Health Care Provider Letter (Niraparib). 2022. https:\/\/www.zejulahcp.com\/content\/dam\/cf-pharma\/hcp-zejulahcp-v2\/en_US\/pdf\/ZEJULA%20(niraparib)%20Dear%20HCP%20Letter%20September%202022.pdf"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30029-4"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.24.00933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T17:59:30Z","timestamp":1744826370000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.24.00933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,20]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,4,20]]}},"alternative-id":["10.1200\/JCO.24.00933"],"URL":"https:\/\/doi.org\/10.1200\/jco.24.00933","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,20]]},"assertion":[{"value":"2024-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}